Find an Article

Filter articles

Applied Filters

Showing 191 to 200 of 288 results

Healthy farms, healthy planet

International11-01-2016Graham Dutfield

Intellectual property rights should be used to help valorise agricultural biodiversity and traditional knowledge for the benefit of the global population as well as small farming communities around the world, says Graham Dutfield of the University of Leeds.

A state of grace

Germany05-01-2016Michael Kahnert

A grace period would give German inventors more flexibility to deal with different rules set by scientific publications and patenting procedures, and allow them to seek patent rights without the fear of prior disclosure, as Michael Kahnert of BIO Deutschland reports.

Jawbone v Fitbit: will fitness trackers be the next IP war?

US22-12-2015Fabio Marino and Luc Dahlin

The smartphone wars may have slowed down but many smaller high-tech companies continue to assert their IP rights against competitors, as the fitness tracker battle shows. Fabio Marino and Luc Dahlin of McDermott Will & Emery report.

IPR and biopharma patents: what the statistics show

International26-11-2015Melissa Gibson and Ruben Munoz

Fewer IPR petitions are instituted against biotech and pharma patents, and there is a higher survival rate of instituted claims in final written decisions compared to all technical fields combined. Melissa Gibson and Ruben Munoz of Akin Gump analyse the statistics.

Biosimilars: Twisting and turning


In July the US Court of Appeals for the Federal Circuit sought to clarify the rules on the ‘patent dance’, but with confusion reigning there are likely to be more twists and turns to come, as LSIPR finds out.

Animal patents: Blurring the lines

EU, US27-10-2015

Patent examiners not only have to tackle legal questions, but in cases of inventions directed to genetically modified animals they must consider moral issues too. This forms part of a wider controversial debate surrounding animals and patents. LSIPR reports.

Amgen v Sandoz: The biosimilars saga continues

US27-10-2015Steve Coyle and Leslie-Anne Maxwell

Despite the US Court of Appeals for the Federal Circuit’s ruling in Amgen v Sandoz, significant uncertainty concerning two key provisions of the BPCIA remains, as Steve Coyle and Leslie-Anne Maxwell of Cantor Colburn describe.

Compulsory licences: Working in the public interest

India27-10-2015Neeti Wilson

Parties can apply for a compulsory licence in India on several grounds, including that the invention is not worked in the country. Neeti Wilson of Anand and Anand explores the issue further.

Traditional knowledge: Protecting age-old practices


Despite the importance of traditional knowledge in many regions, an international treaty governing its control and exploitation does not exist yet—and talks have stalled. LSIPR reports.

Drug patents: A question of morality


Non-profit organisation I-MAK is attempting to expose the problem at the heart of the patent system—that too often drug patents are wrongfully granted and consequently sick people in poorer countries are being left untreated. LSIPR delves deeper into the issues.

Showing 191 to 200 of 288 results